Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tmaid.2020.101812 http://scihub22266oqcxt.onion/10.1016/j.tmaid.2020.101812 32645478!7342171!32645478     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Travel+Med+Infect+Dis 2020 ; 36 (ä): 101812 Nephropedia Template TP {{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials |pdf=|usr=}}{{32645478}} gab.com Text Hydroxychloroquine safety: A meta-analysis of randomized controlled trials JO: Travel Med Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32645478 #FOAvip BACKGROUND: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-analysis to compare the safety of HCQ versus placebo. METHODS: Two authors independently searched PubMed and EMBASE databases for randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ versus placebo for any indication. Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs) were calculated based on random-effects models. The heterogeneity (I(2)) was assessed using Cochran's Q test. RESULTS: Nine RCTs (eight were double-blind) with a total of 916 patients were included. HCQ caused significantly more skin pigmentation than placebo (Peto OR, 4.64; 95% CI, 1.13 to 19.00; P-value = 0.033; I(2) = 0%). The increase in other AEs did not reach statistical significance: rash (Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value = 0.03; I(2) = 0%); gastrointestinal AEs (Peto OR, 1.43; 95% CI, 0.55 to 3.72; P-value = 0.46; I(2) = 15.17%); headache (Peto OR, 1.94; 95% CI, 0.65 to 5.78; P-value = 0.23; I(2) = 9.99%); dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value = 0.58; I(2) = 0%); fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value = 0.15; I(2) = 0%); and visual AEs (Peto OR, 1.61; 95% CI, 0.76 to 3.41; P-value = 0.22; I(2) = 0%). Cardiac toxicity was not reported. CONCLUSIONS: This meta-analysis of RCTs found a significantly higher risk of skin pigmentation in HCQ users versus placebo. More data are needed to evaluate HCQ in the context of COVID-19 treatment. Twit Text FOAVip Hydroxychloroquine safety: A meta-analysis of randomized controlled trials ????Travel Med Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32645478 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32645478 #FOAvip English Wikipedia <ref>{{Cite pmid|32645478}}</ref> Hydroxychloroquine safety: A meta-analysis of randomized controlled trials #MMPMID32645478 Eljaaly K; Alireza KH; Alshehri S; Al-Tawfiq JA Travel Med Infect Dis 2020[Jul]; 36 (ä): 101812 PMID32645478show ga BACKGROUND: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-analysis to compare the safety of HCQ versus placebo. METHODS: Two authors independently searched PubMed and EMBASE databases for randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ versus placebo for any indication. Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs) were calculated based on random-effects models. The heterogeneity (I(2)) was assessed using Cochran's Q test. RESULTS: Nine RCTs (eight were double-blind) with a total of 916 patients were included. HCQ caused significantly more skin pigmentation than placebo (Peto OR, 4.64; 95% CI, 1.13 to 19.00; P-value = 0.033; I(2) = 0%). The increase in other AEs did not reach statistical significance: rash (Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value = 0.03; I(2) = 0%); gastrointestinal AEs (Peto OR, 1.43; 95% CI, 0.55 to 3.72; P-value = 0.46; I(2) = 15.17%); headache (Peto OR, 1.94; 95% CI, 0.65 to 5.78; P-value = 0.23; I(2) = 9.99%); dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value = 0.58; I(2) = 0%); fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value = 0.15; I(2) = 0%); and visual AEs (Peto OR, 1.61; 95% CI, 0.76 to 3.41; P-value = 0.22; I(2) = 0%). Cardiac toxicity was not reported. CONCLUSIONS: This meta-analysis of RCTs found a significantly higher risk of skin pigmentation in HCQ users versus placebo. More data are needed to evaluate HCQ in the context of COVID-19 treatment. |Alzheimer Disease/*drug therapy[MESH] |Antirheumatic Agents/*adverse effects[MESH] |Arthritis, Rheumatoid/drug therapy[MESH] |Asymptomatic Infections[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chronic Urticaria/*drug therapy[MESH] |Coronavirus Infections/drug therapy[MESH] |Dizziness/chemically induced[MESH] |Exanthema/chemically induced[MESH] |Fatigue/chemically induced[MESH] |Gastrointestinal Diseases/chemically induced[MESH] |Glomerulonephritis, IGA/*drug therapy[MESH] |HIV Infections/*drug therapy[MESH] |Headache/chemically induced[MESH] |Humans[MESH] |Hydroxychloroquine/*adverse effects[MESH] |Hyperpigmentation/*chemically induced[MESH] |Lupus Erythematosus, Cutaneous/drug therapy[MESH] |Lupus Erythematosus, Systemic/drug therapy[MESH] |Osteoarthritis/drug therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy[MESH] |Randomized Controlled Trials as Topic[MESH] |Rheumatic Diseases/*drug therapy[MESH]Hydroxychloroquine safety: A meta-analysis of randomized controlled tr(epmc).pdf DeepDyve Pubget Overpricing